Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a medicaid population

Value in Health

Volumn 12, Issue 5, 2009, Pages 708-715

  Yu, Andrew P ^a,c   Atanasov, Pavel ^a   Ben Hamadi, Rym ^a   Birnbaum, Howard ^a   Stensland, Michael D ^b   Philips, Glenn ^b  

^a ANALYSIS GROUP   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c NONE   (United States)

Author keywords

Antipsychotics; Costs; Olanzapine; Optimal matching; Propensity score; Quetiapine; Resource utilization; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; HYPNOTIC SEDATIVE AGENT; MOOD STABILIZER; OLANZAPINE; QUETIAPINE;

ADULT; ALGORITHM; ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG UTILIZATION; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; PRIORITY JOURNAL; REGRESSION ANALYSIS; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COST-BENEFIT ANALYSIS; DIBENZOTHIAZEPINES; DRUG COSTS; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MEDICAID; MIDDLE AGED; PENNSYLVANIA; PROPENSITY SCORE; SCHIZOPHRENIA; UNITED STATES; YOUNG ADULT;

EID: 67649908719     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00498.x     Document Type: Article

References (34)

1. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005 66 : 1122 9.
2. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia (2nd ed.). Arlington, VA : American Psychiatric Association, 2004.
3. Aparasu RR, Bhatara V. Antipsychotic use and expenditure in the United States. Psychiatr Serv 2006 57 : 1693. (Pubitemid 46051321)
4. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006 163 : 611 22.
5. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 353 : 1209 23.
6. Jayaram MB, Hosalli P, Stroup S. Risperidone versus olanzapine for schizophrenia. CD005237. Cochrane Database Syst Rev 2006 19 : CD005237.
7. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003 60 : 553 64.
8. Furtado VA, Srihari V. Atypical antipsychotics for people with both schizophrenia and depression. CD005377. Cochrane Database Syst Rev 2008 1 : CD005377.
9. Rummel C, Hamann J, Kissling W, Leucht S. New generation antipsychotics for first episode schizophrenia. Article no. CD004410. Cochrane Database Syst Rev 2003 4 : CD004410.
10. Sirota P, Pannet I, Koren A, Tchernichovsky E. Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia. Hum Psychopharmacol Clin Exp 2006 21 : 227 34.
11. Sacchetti E, Valsecchi P, Parrinello G. A randomized, flexible - dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLE trial. Schizophr Res 2008 98 : 55 65. (Pubitemid 350245584)
12. Riedel M, Muller N, Spellmann I, et al. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2007 257 : 402 12.
13. Voruganti LP, Awad AG, Parker G, et al. Cognition, functioning and quality of life in schizophrenia treatment: Results of a one-year randomized controlled trial of olanzapine and quetiapine. Schizophr Res 2007 96 : 146 55.
14. Liu GG, Sun SX, Christensen DB, Luo X. Cost comparisons of olanzapine and risperidone in treating schizophrenia. Ann Pharmacother 2004 38 : 134 41.
15. Hargreaves WA, Gibson PJ. Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review. CNS Drugs 2005 19 : 393 410. (Pubitemid 41124014)
16. Liu GG, Sun SX, Christensen DB, Zhao Z. Cost analysis of schizophrenia treatment with second-generation antipsychotic medications in North Carolina's Medicaid program. J Am Pharm Assoc 2007 47 : 77 81.
17. Tunis SL, Ascher-Svanum H, Stensland M, Kinon BJ. Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs. Pharmacoeconomics 2004 22 : 1 8. (Pubitemid 38186956)
18. Yu AP, Ben-Hamadi R, Birnbaum HG, et al. Comparing the treatment patterns of schizophrenia patients treated with olanzapine and quetiapine in Pennsylvania Medicaid population. Current Medical Research Opinion. In press.
19. Gianfrancesco F, Wang RH, Pesa J, Rajagopalan K. Hospitalisation risks in the treatment of schizophrenia in a Medicaid population: comparison of antipsychotic medications. Int J Clin Pract 2006 60 : 1419 24.
20. Gianfrancesco F, Rajagopalan K, Wang RH. Hospitalization risks in the treatment of schizophrenia: comparison of antipsychotic medications. J Clin Psychopharmacol 2006 26 : 401 4.
21. Chen L, McCombs JS, Park J. The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia. Value Health 2008 11 : 34 43. (Pubitemid 351160874)
22. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006 163 : 2080 9.
23. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992 45 : 613 9.
24. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983 70 : 41 55.
25. Austin PC, Mamdani MM. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med 2006 25 : 2084 106.
26. Rosenbaum PR. Observational Studies 2nd ed.). New York : Springer Verlag, 2002.
27. Bergstralh EJ, Kosanke JL, Jacobsen SJ. Software for optimal matching in observational studies. Epidemiology 1996 7 : 331 2.
28. Ho DE, Imai K, King G, et al. Nonparametric preprocessing for parametric causal inference. Available from: http://gking.harvard.edu/matchit/docs/matchit. pdf [Accessed June 25, 2007 RJ, Rubin DB. Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health 2000 21 : 121 45.
29. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006 163 : 2080 9.
30. Gibson PJ, Damler R, Jackson EA, et al. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population. Value Health 2004 7 : 22 35. (Pubitemid 38186282)
31. Wu EQ, Shi L, Birnbaum H, et al. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med 2006 36 : 1535 40.
32. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003 60 : 553 64.
33. Hay JW. Appropriate econometric methods for pharmacoeconometric studies of retrospective claims data: an introductory guide. J Manag Care Pharm 2005 11 : 344 8.
34. Winkelmayer WL, Kurth T. Propensity score: help or hype? Nephrol Dial Transplant 2004 19 : 1671 73.